Steatohepatitis/Metabolic Liver Disease News

Compared with daily calorie restriction, time-restricted eating did not achieve additional benefits for reducing intrahepatic triglyceride content or body fat among patients with nonalcoholic fatty liver disease and obesity.

Although semaglutide did not “significantly improve” fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, notable improvements were reported in cardiometabolic parameters and markers of liver fat and injury.

Lean patients with nonalcoholic fatty liver disease had significantly higher mortality than non-lean patients, despite having lower rates of cirrhosis and diabetes, according to research in Alimentary Pharmacology & Therapeutics.

Physically active patients with nonalcoholic fatty liver disease were more likely to achieve at least a 30% reduction in MRI-measured liver fat, according to research in The American Journal of Gastroenterology.

I never would have thought the debate on nonalcoholic fatty liver disease nomenclature would be as contentious as it is.

This exercise about nonalcoholic fatty liver disease nomenclature is a distraction from what patients really care about.

Regarding the nonalcoholic fatty liver disease nomenclature debate, I am pretty neutral to what the new name should be, and I want to be sensitive to all parties involved.

Many health care providers agree the term nonalcoholic fatty liver disease is a bad name because it’s defining a disease by what it is not; however, the challenge has been to find something that would fulfill a number of criteria.

The term nonalcoholic fatty liver disease has been around for almost three decades and it is an imperfect term, because it uses two controversial words: “nonalcoholic” and “fatty”.

Consuming at least 20% of daily calories from fast food correlated with an increased risk for nonalcoholic fatty liver disease, with more damaging effects among individuals with underlying metabolic comorbidities.